Overview

XRCC5 is altered in 1.25% of all cancers with colon adenocarcinoma, melanoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].

The most common alterations in XRCC5 are XRCC5 Mutation (1.10%), XRCC5 E621K (0.06%), XRCC5 P446S (0.03%), XRCC5 R394* (0.05%), and XRCC5 R599H (0.05%) [3].

Significance of XRCC5 in Diseases

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.